Fulgent Genetics presents FID-007 Phase 2 data at ASCO 2026 meeting
Fulgent announced interim data from its Phase 2 study of FID-007 combined with cetuximab for recurrent/metastatic head and neck cancer, showing 60% objective response rate and favorable safety profile. The presentation at ASCO 2026 could validate the therapeutic potential of the company's oncology pipeline and support future clinical development.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day